Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

http://scihub22266oqcxt.onion/ 1669148!ä!1669148 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Pol+Tyg+Lek 1991 ; 46 (40-42): 739-42 Nephropedia Template TP {{tp|p=1669148|t=1991. Hydrochlorothiazyd, allopurinol i tlenek magnezowy w leczeniu nawrotowej wapniowej kamicy moczowej |pdf=|usr=}}{{1669148}} gab.com Text Hydrochlorothiazyd, allopurinol i tlenek magnezowy w leczeniu nawrotowej wapniowej kamicy moczowej JO: Pol Tyg Lek http://www.kidney.de/pget.php?&tw=1&pmid=1669148 #FOAvip The study aimed at presenting own experience in prevention of new urinary calculi in 18 patients with metabolically active calcium urolithiasis treated with hydrochlorothiazide in daily doses of 100 mg (group I) for 2 years, and in 6 patients with the same disease treated with magnesium oxide in daily doses 300 mg twice a day (group II) for average period of 10 months. In 9 patients a new calculus was formed during the treatment with hydrochlorothiazide, in 7 patients no recurrence was noted, and in 2 remaining patients the results were controversial (coral calculus). Therefore, patients were subdivided into group Ia (failure of hydrochlorothiazide therapy), and group Ib (no recurrence noted). Hydrochlorothiazide did not lead to the stable decrease in the saturation of the urine with calcium oxalate in group Ia whereas in group Ib (without recurrence of urolithiasis) the content of calcium oxalate in the urine was significantly lower than that in group Ia after a 2-year treatment with hydrochlorothiazide (p < 0.01) Recurrence of the disease was seen only in one patient of group II, i.e. treated with magnesium oxide. The treatment of the recurrent calcium urolithiasis is justified and efficient in those patients in whom therapy decreases the content of calcium oxalate in the urine. Twit Text FOAVip Hydrochlorothiazyd, allopurinol i tlenek magnezowy w leczeniu nawrotowej wapniowej kamicy moczowej ????Pol Tyg Lek http://www.kidney.de/pget.php?&tw=1&pmid=1669148 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=1669148 #FOAvip English Wikipedia <ref>{{Cite pmid|1669148}}</ref> Hydrochlorothiazyd, allopurinol i tlenek magnezowy w leczeniu nawrotowej wapniowej kamicy moczowej #MMPMID1669148 Musialik D; Gluszek J; Pieczynska A Pol Tyg Lek 1991[Oct]; 46 (40-42): 739-42 PMID1669148show ga The study aimed at presenting own experience in prevention of new urinary calculi in 18 patients with metabolically active calcium urolithiasis treated with hydrochlorothiazide in daily doses of 100 mg (group I) for 2 years, and in 6 patients with the same disease treated with magnesium oxide in daily doses 300 mg twice a day (group II) for average period of 10 months. In 9 patients a new calculus was formed during the treatment with hydrochlorothiazide, in 7 patients no recurrence was noted, and in 2 remaining patients the results were controversial (coral calculus). Therefore, patients were subdivided into group Ia (failure of hydrochlorothiazide therapy), and group Ib (no recurrence noted). Hydrochlorothiazide did not lead to the stable decrease in the saturation of the urine with calcium oxalate in group Ia whereas in group Ib (without recurrence of urolithiasis) the content of calcium oxalate in the urine was significantly lower than that in group Ia after a 2-year treatment with hydrochlorothiazide (p < 0.01) Recurrence of the disease was seen only in one patient of group II, i.e. treated with magnesium oxide. The treatment of the recurrent calcium urolithiasis is justified and efficient in those patients in whom therapy decreases the content of calcium oxalate in the urine. |Adult[MESH] |Allopurinol/*therapeutic use[MESH] |Calcium Oxalate/urine[MESH] |Female[MESH] |Humans[MESH] |Hydrochlorothiazide/*therapeutic use[MESH] |Magnesium Oxide/*therapeutic use[MESH] |Male[MESH] |Middle Aged[MESH] |Recurrence[MESH]Hydrochlorothiazyd, allopurinol i tlenek magnezowy w leczeniu nawrotow(epmc).pdf DeepDyve Pubget Overpricing